Alexis Ogdie, MD

Rheumatologist, Associate Professor of Medicine
University of Pennsylvania
Philadelphia, PA, United States

I am Associate Professor of Medicine and Epidemiology at the University of Pennsylvania and Deputy Director of the Penn Center for Clinical Epidemiology and Biostatistics. My research program is focused psoriatic arthritis (PsA), an inflammatory arthritis with potentially devastating outcomes that affects around 30% of patients with psoriasis. The mission of my research program is to improve outcomes in PsA through patient-centered research aiming to develop personalized medicine strategies for PsA (including adjunct therapies as proposed here), identify appropriate outcome measures for PsA, and improve early identification of the disease. I am an expert in the care of patients with PsA and founder and Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program. My areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), and more general qualitative methods (e.g., survey, focus group and interview studies). Much of my recent work has been aimed at the design and conduct of randomized controlled trials in PsA with a particular interest in initiating pragmatic trials in PsA.

Disclosure information not submitted.

Presentation(s):

• How to Establish a Career Niche

  Thursday, November 10, 2022
  2:05 PM – 2:40 PM Eastern Time

• Roundtable 08 - How to Establish a Career Niche II

  Thursday, November 10, 2022
  4:00 PM – 4:20 PM Eastern Time

• Roundtable 08 - How to establishi a Career Niche I

  Thursday, November 10, 2022
  3:40 PM – 4:00 PM Eastern Time

• Roundtable 08 - How to Establish a Career Niche III

  Thursday, November 10, 2022
  4:20 PM – 4:40 PM Eastern Time

• Roundtable 08 - How to Establish a Career Niche IV

  Thursday, November 10, 2022
  4:45 PM – 5:05 PM Eastern Time

• Roundtable 08 - How to Establish a Career Niche IV

  Thursday, November 10, 2022
  5:05 PM – 5:25 PM Eastern Time

• 0189: Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study

  Saturday, November 12, 2022
  1:35 PM – 1:40 PM Eastern Time

• 0078: Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 0189: Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time

• 0699: Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time

• 1019: Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time

• 1036: Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time

• 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS

  Sunday, November 13, 2022
  1:35 PM – 1:40 PM Eastern Time

• 1504: Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

  Sunday, November 13, 2022
  3:45 PM – 3:55 PM Eastern Time

• 237: How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?

  Sunday, November 13, 2022
  6:30 PM – 8:30 PM Eastern Time

• Ankylosing Spondylitis: Treat to Target

  Monday, November 14, 2022
  9:00 AM – 9:45 AM Eastern Time

• 250: SPARTAN GRAPPA ASAS SYMPOSIUM on Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis (PsA)

  Tuesday, November 15, 2022
  7:00 AM – 9:30 AM Eastern Time